Outcome and safety of TNFα antagonist therapy in 475 consecutive outpatients (with rheumatoid arthritis or spondyloarthropathies) treated by a single physician according to their eligibility for clinical trials

Patients meeting the selection criteria used in pivotal trials had a higher response rate and significantly fewer serious adverse events.